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Introduction:
In the initial year of the grant, we have carried out the bulk of the studies to characterize breast cancer cell lines with respect to overexpression of cyclin Dl protein and the presence of Rb (retinoblastoma) protein (Specific Aim No. 1). In addition, we have begun examination of surgically obtained breast cancer tissue samples for cyclin Dl protein overexpression and Rb protein content (Specific Aim No. 6).
Since the original grant proposal was submitted, advances in our understanding of cell cycle regulation, and in particular advances in our understanding of the importance of defects in cell cycle regulation to the development of cancer, have proceeded at a rapid pace( )( ). In order to incorporate these advances into our investigation of cell cycle regulatory defects in breast cancer, we have expanded and reoriented some aspects of our approach. This has included a detailed assessment of the levels of cyclin dependent kinase (cdk) 4 and cdk 6, and of the cdk4/cdk6-specific cdk inhibitor protein pl6 (see Results below). This reorientation of the investigation in the light of ongoing research advances can be accommodated within the framework of the originally requested funds and resources.
Materials and Methods:
Breast cancer cell lines and tumor material A panel of 13 breast cancer cell lines were obtained both from the American Type  Culture Collection (BT-483, DU4475, MDA-MB-157, MDA-MB-175VH, MDA-MB-361,  MDA-MB-415 and Hs578T) , and the University of Colorado Tissue Culture Core Faculty (COLO 591, MCF-7, MDA-MB-231, MDA-MB-330, T47-D and ZR75.1). Two normal, immortalized, breast epithelial cell lines, MCF-10A and MCF-12A, and one normal breast epithelium cell line transformed with SV40 T antigen (TAg), HBL-100, were also obtained from the University of Colorado Tissue Culture Core Facility. The cell lines BT-483, COLO 591 and DU4475 were cultured in RPMI 1640 media supplemented with 10% fetal calf serum, 0.2% sodium bicarbonate, 18 mM HEPES, 1% non-essential amino acids, 1 mM sodium pyruvate and 2 mM L-glutamine. MCF-10A and MCF-12A were cultured in Hams F12/DME (1:1) supplemented with 10% fetal calf serum, 20 ng/ml EGF, 500 ng/ml hydrocortisone, 100 ng/ml cholera toxin and 10 ng/ml insulin. Hs578T was cultured in DMEM media supplemented with 10% fetal calf serum, 0.45% glucose, 0.4% sodium bicarbonate and 2 mM L-glutamine. The remaining cell lines were cultured in MEM media supplemented with 10% fetal calf serum, 0.2% sodium bicarbonate, 10 mM HEPES, 1% non-essential amino acids, 2 mM L-glutamine and 6 ng/ml insulin.
Three unmatched frozen tumor samples and one matched pair of frozen non-tumor and tumor tissues from breast cancer patients undergoing mastectomy were provided by Dr. Wilbur Franklin, University of Colorado Cancer Center Tissue Procurement Core, University of Colorado Medical School.
Antibodies
The following primary antibodies were obtained from Upstate Biotechnology, Lake Placid, NY: anti-cyclin Dl, anti-cdk4, anti-cdk6, and anti-PSTAIRE kinase. Anti-cyclin E and anti-pl6 were obtained from Pharmingen, and anti-pRb was a gift from Dr. Wen-Hua Lee (University of Texas Health Science Center, San Antonio, TX). The horseradish peroxidase-conjugated secondary antibodies were from Bio-rad.
Protein extractions
Cell lines. Cells were harvested from each of two 175 cm^ flasks at 50-70% confluence. Following resuspension in PBS approximately 2 X 10 6 cells were removed for fluorescence-activated cell sorter (FACS) analysis by the University of Colorado Cancer Center Flow Cytometry Core to determine cell cycle distribution. The remaining cells were resuspended in 4 X Laemmli sample buffer (Laemmli., 1970) , boiled for 4 minutes, sheared through a 26-gauge syringe needle, aliquoted, and stored at -80°C.
Tissue samples. Individual pieces of tumor and non-tumor tissues each weighing approximately 0.2 g, were crushed to a fine powder under liquid nitrogen, lysed in 4 X Laemmli sample buffer and processed as described above for the cell lines.
Western Analysis
Approximately 50 \ig of each protein extract were subjected to SDS/PAGE (Laemmli., 1970) and transferred either to nitrocellulose (Schleicher and Schuell) for future probing with the anti-pl6 antibody or Immobilon P (Amersham) membranes for 45 minutes at 0.45 A using the Genie Electrophorectic Blotter (Idea Scientific, Minneapolis). Membranes were stained with Ponceau dye to control for equal loading and immunodetection performed using the enhanced chemiluminescence (ECL) kit (Amersham) according to the manufacturer's instructions.
Results:
A breast cancer panel was assembled consisting of 13 breast cancer cell lines, three nontumor cell lines, one pair of non-tumor and tumor tissues derived from a breast cancer patient, and three unpaired tumor tissues derived from breast cancer patients. The tumors and cell lines involved in this study represent several different histopathological types and were derived from both primary tumors and metastatic deposits. The ages of the women from whom tumors originated ranged from 23-74 years (Table 1) .
Cultures of the cell lines were harvested for protein extraction at 50-70% confluence and their cell cycle distribution assessed by FACs analysis. The percentage of cells in S-phase ranged from approximately 15% to 40%. Approximately 50 ^.g of protein derived from both the cell lines and tumor samples were subjected to SDS/PAGE, blotted, and probed with 8 anti-cell cycle protein antibodies. The cell lines were initially immunoblotted with the anti-Human cdc2 Kinase (PSTAIRE), the latter of which appears to be expressed at relatively constant levels in the cell lines. The same pattern of expression was demonstrated following immunoblotting with an antibody specific for one of the PSTAIRE sequence-containing proteins, Cdk2 (Fig.2 and Table  3 ).
Cyclin Dl and Rb protein expression in breast cancer cell lines and tumors.
Following immunoblotting with anti-Cyclin Dl and anti-Rb antibodies the cell lines and tumors were classified into one of four groups: those that (1) showed the amplification of Cyclin Dl protein in the presence of functional pRb (ie., the hypophosphorylated, active form of pRb); (2) showed the absence/very low level of Cyclin Dl in the absence of functional pRb; (3) showed absence/very low level of Cyclin Dl in the presence of functional pRb; and (4) Table 2 and Fig. 1 . Furthermore, the control cell line, HBL-100, that expresses the SV40 Tag (and thus lacks functional pRb), also exhibits very low levels of Cyclin Dl protein. This is consistent with the model that abnormally elevated levels of Cyclin Dl protein are required to overcome the active pRb-mediated Gl/S block in breast cancer cells. The correlation between Cyclin Dl overexpression and the presence of functional Rb protein has previously been demonstrated both in non-small cell lung cancer (Schauer et al., 1994) and esophageal cancer (Jiang et al., 1993) . Three of the tumor cell lines, COLO 591, ZR75.1 and MDA-MD-175VII displayed an inverse correlation between the levels of pRb and Cyclin Dl protein (group 4) indicating that these cell lines employed different mechanisms to escape the normal cell growth controls. None of the cell lines nor tumor tissues were classified into group 3.
Expression of Cyclin Dl-associated Cdk4 and Cdk6 proteins in breast cancer cell lines and tumors.
The levels of the Cyclin Dl-associated Cdk4 and Cdk6 proteins remain relatively constant during the normal cell cycle with oscillations in Kinase activity controlled by Cyclin Dl (Hunter and Pines., 1994) . Characterization of these proteins in the breast cancer cell lines involved the use of the specific Cdk4 and Cdk6 immunizing peptides to block non-specific antibody binding. Three of the eight tumor cell lines, MCF-7, MDA-MB-231 and ZR75.1, and the non-tumor cell line, HBL-100 (SV40 Tag-transformed) cell line exhibit elevated levels of Cdk4 protein relative to the other tumor cell tines and non-tumor control cell lines. By contrast, the levels of Cdk6 protein do not appear to be significantly increased in the majority of breast cancer cell lines nor tumors tissues relative to the non-tumor controls (Table 3 and Fig. 2 ). Furthermore two of the breast cancer cell lines and one of the non-SCLC control cell lines lack detectable Cdk6 protein. This suggests differences in the potentially oncogenic activities of Cdk4 and Cdk6 during tumorigenesis in different breast tumors. Previous studies have indicated possible oncogenic roles for Cdk4 and Cdk6 in tumorigenesis. Tarn et al. (1994) described the overexpression of the Cdk6 protein in some types of tumor, and amplification of the both the Cdk4 gene (Khabtib et al., 1993) and the Cdk4 protein (Tarn et al., 1994) has been demonstrated in several tumors including breast cancer. Furthermore, a mutated Cdk4 protein has been identified in two primary melanoma tumors that prevents binding of the Cdk-inhibitor, pi6, resulting in constitutively active Cyclin Dl/Cdk4 complexes (Wolfel et al., 1995) . The above data suggest that Cdk4 has the potential to contribute to tumorigenesis through at least two pathways: aberrant overexpression or mutation, resulting in the inhibition of pl6-mediated cell cycle regulation.
Expression of the Cdk4-inhibitor pl6 is restricted to breast cancer cell lines lacking functional pRb.
The expression of pl6 is restricted to two of the cell lines that lack functional pRb and exhibit elevated levels of Cdk4 protein:-HBL-100 and MDA-MB-231 (Table 3 and Fig. 2) . The breast cancer cell line, MCF-7, exhibits elevated levels of Cdk4 protein but contains functional pRb (and has been shown to contain an active Cyclin Dl/Cdk4 complex by Tarn et al., (1994) ) and thus does not exhibit detectable levels of pi6. These findings are consistent with the model that active pRb inhibits pi6 expression and that the loss of Rb protein allows the p 16 protein to bind to Cdk4 resulting in the dissociation and inactivation of the Cyclin Dl/Cdk4 complex. It is possible that the elevated levels of Cdk4 in MDA-MB-231 may contribute towards overriding the growth regulatory function of pi6. It is also possible that MDA-MB-231 contains a mutant Cdk4 protein that prevents binding of pl6. Three of the breast tumor tissue samples and the non-tumor tissue control also show varying levels of pl6 expression. However, both the non-tumor control and the tumor sample 92 1908 (T) contain low levels of functional pRb. This result suggests that low level expression of pRb may not suffice to completely inhibit p 16 expression in breast tissues.
Amplification of Cyclin E protein occurs in a minority of breast cancer cell lines and tumors.
The expression of Cyclin E protein appears to be maintained at a relatively high level in both the breast cancer cell lines and the non-tumor cell lines, MCF-12A and HBL-100 (Table 3 and Fig. 2 ). In addition, the breast cancer cell line, DU4475 appears to show unusually high levels of the protein relative to the rest of the panel. Since DU4475 lacks functional pRb and thus expresses only a low level of Cyclin Dl protein, it is possible that Cyclin E may play an potentially oncogenic role in late Gl to ensure maintenance of the transformed state. Two of the four tumors also show elevated levels of Cyclin E relative to the normal tissue control and other tumor samples. Like DU4475, one of these tumors, S92 4153 (T), exhibits low levels of Cyclin Dl protein owing to the lack of functional pRb, whereas the other tumor, 92 1908 (T), contains functional pRb and exhibits significant over-expression of Cyclin Dl. The latter case suggests that one mechanism of oncogenic transformation in breast tumors involves the sequential phosphorylation (and thus inactivation) of pRb by Cyclins Dl and E (in complex with their catalytic subunits) in mid and late Gl phase respectively, resulting in the inappropriate transition into S-phase. Since the levels of the Cdk2 protein remain relatively constant in the breast cancer cell lines and non-tumor cell lines, it is likely that any potential role in tumorigenesis is achieved by modulation of their catalytic activity by Cyclin E as opposed to changes in the absolute level of protein. ^is patient did not receive radiation prior to surgery. Tumor and non-tumor tissues are designated by the patient's number followed by (T) or (N) respectively. The table contains the following abbreviations :-ca, carcinoma; (iv), invasive; Adeno, Adenocarcinoma; Pleural eff., Pleural effusion; Rad, Radiation; Chemo, Chemotherapy; and Surg, Surgery. 
